Supplementary Table 6 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
Year: 2025
Type: supplementary-materials
Abstract: Phase 1 FHD-609 in Synovial Sarcoma, SMARCB1-Deficient Tumors Supplementary Table 6.Adverse events leading to treatment discontinuation in patients with advanced synovial sarcoma or SMARCB1-deficient tumors treated with FHD-609. AEs leading to treatment discontinuation
Authors: J. Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik, Mrinal Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás-Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros-Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan, Ariel Lefkovith, Scott Innis, Alexander J. Lazar, Gregory M. Cote, Andrew J. Wagner
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4407667262